- Home
- MNOV vs TLSA Comparison
MNOV vs TLSA Comparison
Compare MNOV & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNOV
- TLSA
- Stock Information
- Founded
- MNOV 2000
- TLSA 2013
- Country
- MNOV United States
- TLSA United Kingdom
- Employees
- MNOV N/A
- TLSA N/A
- Industry
- MNOV Biotechnology: Pharmaceutical Preparations
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- MNOV Health Care
- TLSA Health Care
- Exchange
- MNOV Nasdaq
- TLSA Nasdaq
- Market Cap
- MNOV 65.7M
- TLSA 187.0M
- IPO Year
- MNOV 2005
- TLSA 2000
- Fundamental
- Price
- MNOV $1.23
- TLSA $1.68
- Analyst Decision
- MNOV Strong Buy
- TLSA
- Analyst Count
- MNOV 2
- TLSA 0
- Target Price
- MNOV $7.00
- TLSA N/A
- AVG Volume (30 Days)
- MNOV 65.0K
- TLSA 333.7K
- Earning Date
- MNOV 11-12-2025
- TLSA 05-06-2025
- Dividend Yield
- MNOV N/A
- TLSA N/A
- EPS Growth
- MNOV N/A
- TLSA N/A
- EPS
- MNOV N/A
- TLSA N/A
- Revenue
- MNOV $134,599.00
- TLSA N/A
- Revenue This Year
- MNOV N/A
- TLSA N/A
- Revenue Next Year
- MNOV N/A
- TLSA N/A
- P/E Ratio
- MNOV N/A
- TLSA N/A
- Revenue Growth
- MNOV N/A
- TLSA N/A
- 52 Week Low
- MNOV $1.13
- TLSA $0.63
- 52 Week High
- MNOV $2.55
- TLSA $2.60
- Technical
- Relative Strength Index (RSI)
- MNOV 37.77
- TLSA 43.82
- Support Level
- MNOV $1.25
- TLSA $1.51
- Resistance Level
- MNOV $1.38
- TLSA $1.88
- Average True Range (ATR)
- MNOV 0.05
- TLSA 0.16
- MACD
- MNOV -0.01
- TLSA -0.01
- Stochastic Oscillator
- MNOV 0.00
- TLSA 34.69
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.